Company: DNLI
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001628280-25-008647
Chunk: 37

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 37
---
 independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 , and the effectiveness of our internal control over financial reporting as of December 31, 2024 , as set forth in their reports, which are incorporated by reference in this prospectus supplement and the accompanying prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP's reports, given on their authority as experts in accounting and auditing.

### WHERE YOU CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement on Form S-3 under the Securities Act of 1933, as amended, or the Securities Act, with respect to the common stock offered by this prospectus supplement. This prospectus supplement, filed as part of the registration statement, does not contain all the information set forth in the registration statement and its exhibits and schedules, portions of which have been omitted as permitted by the rules and regulations of the SEC. For further information about us, we refer you to the registration statement and to its exhibits and schedules.

We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC’s website at www.sec.gov . Copies of certain information filed by us with the SEC are also available on our website at www.denalitherapeutics.com . Information accessible on or through our website is not a part of this prospectus.

<div align='center'>S-21</div>

#### Up to $400,000,000

#### Common Stock
<div align='center'>________________________________________</div>

### PROSPECTUS SUPPLEMENT
<div align='center'>________________________________________</div>

| Goldman Sachs & Co. LLC |     | Leerink Partners |

#### February 27, 2025
#### ________________________________________

# PART II

### INFORMATION NOT REQUIRED IN PROSPECTUS

## Item 14. Other Expenses of Issuance and Distribution
The following is an estimate of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securities being registered hereby.

| SEC registration fee                                        |     |   |    | -1)(2 |
| Printing expenses                                           |     |   | -2 |       |
| Legal fees and expenses (including Blue Sky fees)           |     |   | -2 |       |
| Accounting fees and expenses